ANÆSTESIKLINIKKEN ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.9% 2.2% 1.9% 37.5% 36.4%  
Credit score (0-100)  72 67 70 0 0  
Credit rating  A BBB A C C  
Credit limit (kDKK)  1.2 0.1 1.1 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  5,995 6,642 6,268 8,116 -16.0  
EBITDA  2,062 2,508 2,013 7,966 -16.0  
EBIT  1,977 2,451 2,009 7,966 -16.0  
Pre-tax profit (PTP)  1,998.4 2,484.8 2,167.4 8,231.3 -19.9  
Net earnings  1,565.4 1,936.5 1,719.3 6,425.6 -19.9  
Pre-tax profit without non-rec. items  1,998 2,485 2,167 7,931 -19.9  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  56.7 0.0 623 0.0 0.0  
Shareholders equity total  1,797 2,024 1,823 239 98.8  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,339 2,707 2,968 357 111  

Net Debt  -1,151 -367 -466 -229 -111  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  5,995 6,642 6,268 8,116 -16.0  
Gross profit growth  16.6% 10.8% -5.6% 29.5% 0.0%  
Employees  1 2 2 2 0  
Employee growth %  0.0% 100.0% 0.0% 0.0% -100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,339 2,707 2,968 357 111  
Balance sheet change%  8.0% 15.8% 9.6% -88.0% -68.8%  
Added value  1,976.7 2,451.1 2,009.3 7,965.8 -16.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -170 -113 619 -623 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 -1.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  33.0% 36.9% 32.1% 98.2% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  89.6% 99.4% 76.6% 481.6% -6.9%  
ROI %  114.3% 131.2% 112.3% 768.7% -9.5%  
ROE %  88.7% 101.4% 89.4% 623.3% -11.8%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  76.9% 74.7% 61.4% 66.9% 88.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -55.8% -14.6% -23.1% -2.9% 693.8%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  3.7 3.5 1.8 3.0 9.0  
Current Ratio  3.7 3.5 1.8 3.0 9.0  
Cash and cash equivalent  1,150.9 366.7 465.5 229.3 111.2  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,445.1 1,676.3 891.0 238.7 98.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  1,977 1,226 1,005 3,983 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  2,062 1,254 1,007 3,983 0  
EBIT / employee  1,977 1,226 1,005 3,983 0  
Net earnings / employee  1,565 968 860 3,213 0